Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders?
Halper Sadeh LLC, an investor rights law firm, announced it is investigating Fulcrum Therapeutics' merger with Slate Medicines, under which Fulcrum shareholders are expected to own just 5.0% of the combined company. The same release also targets Weave Communications' $7.40-per-share cash sale to Francisco Partners and Bio-Techne's $73.00-per-share cash sale to Merck KGaA, and says the firm may seek increased consideration or additional disclosures.
Key figures
- Tech deal price
- $73.00 per share in cash
- Weav deal price
- $7.40 per share in cash
- Fulc pro forma ownership
- 5.0%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.